State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China.
Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Front Immunol. 2022 Jan 31;13:822210. doi: 10.3389/fimmu.2022.822210. eCollection 2022.
In HIV infection, some closely associated human leukocyte antigen (HLA) alleles are correlated with distinct clinical outcomes although presenting the same HIV epitopes. The mechanism that underpins this observation is still unknown, but may be due to the essential features of HLA alleles or T cell receptors (TCR). In this study, we investigate how T18A TCR, which is beneficial for a long-term control of HIV in clinic, recognizes immunodominant Gag epitope TL9 (TPQDLTML180-188) from HIV in the context of the antigen presenting molecule HLA-B81:01. We found that T18A TCR exhibits differential recognition for TL9 restricted by HLA-B81:01. Furthermore, structural and biophysical approaches, we observed that TL9 complexes with HLA-B81:01 undergoes no conformational change after TCR engagement. Remarkably, the CDR3β in T18A complexes does not contact with TL9 at all but with intensive contacts to HLA-B81:01. The binding kinetic data of T18A TCR revealed that this TCR can recognize TL9 epitope and several mutant versions, which might explain the correlation of T18A TCR with better clinic outcomes despite the relative high mutation rate of HIV. Collectively, we provided a portrait of how CD8 T cells engage in HIV-mediated T cell response.
在 HIV 感染中,一些密切相关的人类白细胞抗原(HLA)等位基因与不同的临床结果相关,尽管它们呈现出相同的 HIV 表位。这种观察结果的机制尚不清楚,但可能是由于 HLA 等位基因或 T 细胞受体(TCR)的基本特征。在这项研究中,我们研究了 T18A TCR 如何在 HLA-B81:01 呈递分子的背景下识别 HIV 中的免疫优势 Gag 表位 TL9(TPQDLTML180-188),T18A TCR 在临床上有利于长期控制 HIV。我们发现 T18A TCR 对受 HLA-B81:01 限制的 TL9 表现出不同的识别。此外,通过结构和生物物理方法,我们观察到与 HLA-B81:01 结合的 TL9 复合物在 TCR 结合后不会发生构象变化。值得注意的是,T18A 复合物中的 CDR3β 根本不与 TL9 接触,而是与 HLA-B81:01 接触密切。T18A TCR 的结合动力学数据表明,该 TCR 可以识别 TL9 表位和几个突变版本,这可能解释了尽管 HIV 的突变率相对较高,但 T18A TCR 与更好的临床结果相关的原因。总之,我们提供了一幅 CD8 T 细胞如何参与 HIV 介导的 T 细胞反应的图景。